Ingia Bio received “no questions” letters from FDA for three ingredients

Ingia Bio, an ingredient manufacturer and food technology company, has recently received three “no questions” letters from the Food and Drug Administration in response to GRAS (generally recognized as safe) notifications it had submitted in 2024.

The three ingredients are rebaudioside I, D-psicose, and rebaudioside M.

Ingia Bio president Sherry Guo explained to Nutritional Outlook that the company is one of the few, if not the only, stevia ingredient supplier to hold GRAS for both bioconverted and fermented rebaudioside M.

Rebaudioside I is a general-purpose sweetener, obtained through purified components of leaves of the stevia plant. Rebaudioside I is intended for food products and has a “relative sweetness intensity as low as 170 times that of sucrose.”

Next, the sweetener D-psicose (also known as D-allulose) is intended for use in several food categories – also including low-calorie or sugar-free versions of foods and beverages – including bakery products, non-alcoholic beverages, cereals, chewing gum, coffee mix, and more, at levels ranging from 2% to 100%. It is made from a non-pathogenic and non-toxigenic strain of Escherichia coli K-12 MG1655-DPE-01.

Third, rebaudioside M, a glycoside of steviol, is made from a modified non-pathogenic and non-toxigenic strain of Escherichia coli BL21(DE3) and is intended as a sweetener for foods.

The three letters note that the ingredients are not intended for infant formula or infant foods or products under USDA jurisdiction.